Journal
CANCER IMMUNOLOGY RESEARCH
Volume 9, Issue 10, Pages 1110-1110Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2326-6066.CIR-21-0556
Keywords
-
Categories
Funding
- NCI NIH HHS [P01 CA065493] Funding Source: Medline
Ask authors/readers for more resources
The development of a novel biological molecule described in this study aims to target IL15 to tumor-infiltrating lymphocytes effectively, reducing systemic toxicities and enhancing antitumor responses.
The advent of checkpoint blockade and use of cytokines to enhance immune responses have changed the field of immunotherapy. Yet, these approaches are not without drawbacks including systemic toxicities and acquired therapeutic resistance. In this issue, Xu and colleagues describe a novel biological molecule composed of a PD-1-targeting antibody linked to a mutated IL15 that induces better targeting of IL15 to tumor-infiltrating lymphocytes (TIL) to decrease systemic toxicities and enhance antitumor responses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available